Journal article icon

Journal article

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Abstract:

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess the efficacy and safety of selumetinib plus docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma. PATIENTS AND METHODS: In this double-blind multicentre phase II trial...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mdu054

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences
Larkin, JM More by this author
Expand authors...
Publisher:
Oxford University Press
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume:
25
Issue:
5
Pages:
968-974
Publication date:
2014-05-05
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
URN:
uuid:429964d3-b5e8-4130-a3fb-d344487543f3
Source identifiers:
449685
Local pid:
pubs:449685

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP